UCB gets $120m up front from Roche for option rights to UCB0107 and retains full rights to the drug in progressive supranuclear palsy.

Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.

As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

Dementia is one of the world’s greatest health care challenges. Globally, there is a new case of dementia every three seconds, adding up to around 50 million people worldwide. While it is good news that people are living longer, healthier lives, by 2050 the number of people with dementia is predicted to more than triple, reaching around 152 million.